|
Islet Cell Transplants for Diabetes Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Islet Cell Transplants for Diabetes conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Islet Cell Transplants for Diabetes Clinical research trials and Islet Cell Transplants for Diabetes health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Islet Cell Transplants for Diabetes. Islet Cell Transplants for Diabetes Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Islet Cell Transplants for Diabetes clinical trial. Human subjects frequently get the finest healthcare available for their Islet Cell Transplants for Diabetes condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Islet Cell Transplants for Diabetes  Islet Cell Transplants for Diabetes
Islet Cell Transplants for Diabetes
For Condition: Diabetes Mellitus, Insulin-Dependent
Status: No longer recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The purpose of this study is to test whether the islet cell transplantation procedures and results from a previous study in Edmonton, Canada, can be repeated. The study also is designed to learn more about diabetes control using islet cell transplantation. This is a Phase I/II study (a study that examines effectiveness and looks for side effects). The transplanting of islet cells has been studied in Type 1 diabetic patients whose blood sugar levels will not stay normal, despite intensive insulin therapy. A recent study conducted in Edmonton, Canada, was able to demonstrate that islet transplantation led to insulin independence in a majority of the patients treated. This study extends the results obtained from the Edmonton study, which used islet transplantation in Type 1 diabetic patients with steroid-free immunosuppression.
Details: This is a Phase I/II study (a study that examines effectiveness and looks for side effects). The transplanting of islet cells has been studied in Type 1 diabetic patients whose blood sugar levels will not stay normal, despite intensive insulin therapy. A recent study conducted in Edmonton, Canada, was able to demonstrate that islet transplantation led to insulin independence in a majority of the patients treated. This study extends the results obtained from the Edmonton study, which used islet transplantation in Type 1 diabetic patients with steroid-free immunosuppression. Eligible patients were randomly selected from the total pool of people who applied through the Immune Tolerance Network. Patients will receive at least 10,000 "islet equivalents" per kilogram (2.2 pounds) of body weight. This likely will require 2 separate islet infusions from 2 separate donors. Immediately before the first transplant, patients will be given anti-rejection (immune suppressing) drugs, including tacrolimus and sirolimus (orally) and daclizumab (intravenously). The islets will be infused into the liver through a tube placed in the portal vein. Heparin (a medication to prevent blood clots) will be administered with the islet infusion. A longer-acting form of heparin will also be given by daily injections during the next week after each transplant. After surgery, patients will receive insulin intravenously for 24 hours. Patients will have an abdominal ultrasound and blood tests to determine liver function. If fewer than 10,000 islets were transplanted, patients will continue insulin treatment, with the dosages adjusted if necessary to account for the transplanted islets. They will take daclizumab every 2 weeks for 8 weeks and tacrolimus and sirolimus daily. Patients will be given antibiotics to prevent infections. Blood tests to see how much immunosuppressant drug is in the blood will be performed until the drug is at a stable level. Periodically there will be tests to see if the islet cells are functioning. Blood will be drawn to check drug levels and for other tests routinely. Daily insulin requirements will be checked, and these will be recorded monthly. Patients will be followed for at least 1 year post final transplant. Additional follow-up may be provided at least annually for up to 5 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients may be eligible for this study if they: - Have had Type 1 diabetes mellitus for more than 5 years, and are exhibiting 1 of the following, despite intensive insulin management efforts: a) hypoglycemic unawareness, as defined by inability to sense hypoglycemia until the blood glucose falls to less than 54 mg/dl; b) metabolic instability, with 2 or more episodes of severe hypoglycemia (defined as an event with symptoms consistent with hypoglycemia in which the patient requires the assistance of another person and which is associated with a blood glucose below 54 mg/dl) or 2 or more hospital visits for diabetic ketoacidosis over the last year; or c) despite efforts at optimal glucose control, progressive secondary complications of diabetes as defined by retinopathy, nephropathy, or neuropathy. - Are 18 to 65 years of age. Exclusion Criteria Patients will not be eligible for this study if they: - Have had severe cardiac disease as defined by: a) recent myocardial infarction within the past 6 months; b) angiographic evidence of non-correctable coronary artery disease; or c) evidence of ischemia on a functional cardiac exam. - Actively abuse alcohol or substances, including cigarette smoking (must not have smoked within the last 6 months). - Have psychiatric problems that prevent them from being a suitable candidate for transplantation (such as schizophrenia, bipolar disorder, or major depression that is not controlled or stable on current medication). - Have a history of not following prescribed regimens. - Have active infection including hepatitis C, hepatitis B, HIV, or TB (or under treatment for suspected TB). - Have a history of malignancy, except squamous or basal skin cancer. - Weigh more than 70 kg or have a BMI greater than 26 kg/m2 at time of screening. - Have a C-peptide value of 0.3 ng/ml or more following a 5.0 gram intravenous arginine infusion. - Are unable to provide informed consent. - Have gallstones or hemangioma in liver. - Have untreated proliferative retinopathy. - Are breast-feeding or pregnant, or intend to try and become pregnant (females) or to father a child (males), or fail to follow birth control methods. - Have had a previous transplant, or evidence of anti-HLA antibody. - Have an insulin requirement of more that 0.7 IU/kg/day. - Have an HbA1c higher than 12 percent. - Are unable to reach the hospital for transplantation within 2 hours of notification. - Have untreated or treated hyperlipidemia. - Have a medical condition requiring chronic use of steroids. - Use coumadin or other anticoagulants (aspirin is allowed). - Have Addison's disease. - Have a negative screen for Epstein-Barr virus (EBV).
Total Enrollment: 40
Location and Contact Information:
Overall Study Official:
JamesShapiro, Principal Investigator,
Immune Tolerance Network
Chicago, Illinois, 60637
United States
Additional Information:
Study ID Numbers: DAIT NIS01;
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00014911
Other Diabetes Mellitus, Insulin-Dependent Studies:
1. Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes
2. LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes.
3. Continuous Glucose Monitors for Children With Diabetes Mellitus
4. Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)
5. Continuous Glucose Monitoring in Children With Type 1 Diabetes Mellitus
Related Studies:
Other Diabetes Mellitus, Insulin-Dependent Clinical Trials
Other Illinois Clinical Trials
Other Chicago Clinical Trials
Islet Cell Transplants for Diabetes
|
|
|
|
|
|
|
|
